Edition:
United States

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

4.45USD
25 Sep 2018
Change (% chg)

$0.25 (+5.95%)
Prev Close
$4.20
Open
$4.25
Day's High
$4.65
Day's Low
$4.25
Volume
19,620
Avg. Vol
26,596
52-wk High
$8.80
52-wk Low
$3.65

Latest Key Developments (Source: Significant Developments)

Cidara Therapeutics Says On Sept. 6, Increased Authorized Size Of Board Members From 6 To 7
Wednesday, 12 Sep 2018 05:06pm EDT 

Sept 12 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS - ON SEPT. 6, UPON RECOMMENDATION OF BOARD, APPROVED INCREASE IN AUTHORIZED SIZE FROM 6 TO 7 BOARD MEMBERS - SEC FILING.  Full Article

Cidara Therapeutics Says Matthew Onaitis Resigned As CFO
Friday, 17 Aug 2018 04:36pm EDT 

Aug 17 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS SAYS EFFECTIVE AUG 17, MATTHEW ONAITIS RESIGNED FROM POSITIONS AS CFO - SEC FILING.  Full Article

Cidara Announces Stock And Warrants Offering Worth $120 Mln
Monday, 21 May 2018 07:30am EDT 

May 21 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS.CIDARA THERAPEUTICS - ENTERED SECURITIES PURCHASE DEAL WITH CERTAIN INVESTORS PROVIDING FOR PURCHASE, SALE OF UP TO $120 MILLION OF ITS COMMON STOCK.CIDARA THERAPEUTICS INC - CIDARA WILL OFFER ABOUT 10.6 MILLION SHARES OF COMMON STOCK IN FIRST CLOSING OF OFFERING AT $4.70 PER SHARE.CIDARA THERAPEUTICS - ENTERED SECURITIES PURCHASE AGREEMENT FOR PURCHASE &SALE, OF UP TO AGGREGATE OF $120.0 MILLION OF ITS COMMON STOCK, IN 3 CLOSINGS.CIDARA - ALSO SELLING TO MAJOR PURCHASERS WARRANTS, AT $0.125/SHARE SUBJECT TO EACH SUCH WARRANT, TO PURCHASE AGGREGATE 12.5 MILLION SHARES OF STOCK.  Full Article

Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin
Monday, 19 Mar 2018 07:30am EDT 

March 19 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN.CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN.CIDARA THERAPEUTICS INC - ‍PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018​.CIDARA THERAPEUTICS INC - PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018.CIDARA THERAPEUTICS - ‍FAVORABLE SAFETY,TOLERABILITY,EFFICACY OBSERVED IN ONCE-WEEKLY ECHINOCANDIN FOR DIFFICULT-TO-TREAT INVASIVE FUNGAL INFECTIONS​.CIDARA THERAPEUTICS INC - ‍STRIVE MET ALL OF ITS PRIMARY OBJECTIVES​.CIDARA THERAPEUTICS INC - ‍THERE WERE NO CONCERNING TRENDS IN ADVERSE EVENTS OBSERVED​.CIDARA THERAPEUTICS-THERE WERE 2 SERIOUS ADVERSE EVENTS POSSIBLY RELATED TO STUDY DRUG: ONE IN GROUP 2, ONE IN GROUP 3; BOTH PATIENTS FULLY RECOVERED​.CIDARA THERAPEUTICS INC - ‍ PHASE 3 RESPECT PROPHYLAXIS TRIAL EXPECTED TO PRODUCE AN INTERIM FUTILITY READ-OUT IN 2019, PROVIDE TOPLINE RESULTS IN 2020​.  Full Article

Cidara Posts Q4 Loss Per Share $0.69​
Tuesday, 27 Feb 2018 04:31pm EST 

Feb 27 (Reuters) - Cidara Therapeutics Inc ::CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.CIDARA THERAPEUTICS INC QTRLY LOSS PER SHARE $0.69​.  Full Article

Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin
Tuesday, 28 Nov 2017 08:30am EST 

Nov 28 (Reuters) - Cidara Therapeutics Inc ::CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS.  Full Article

Cidara reports qtrly ‍basic and diluted net loss per share $0.73​
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Cidara Therapeutics Inc ::Cidara provides corporate update and reports third quarter 2017 financial results.Cidara Therapeutics Inc - qtrly ‍basic and diluted net loss per share $0.73​.Cidara Therapeutics Inc - qtrly ‍total operating expenses $12.2 million versus $12.3 million.Q3 earnings per share view $-0.94 -- Thomson Reuters I/B/E/S.  Full Article

T2 Biosystems, Cidara Therapeutics enter partnership for commercial placement of T2Dx instruments
Wednesday, 6 Sep 2017 11:05am EDT 

Sept 6 (Reuters) - T2 Biosystems::Co, Cidara Therapeutics entered into exclusive partnership for commercial placement of T2Dx instruments to support CD101 drug trials​.Program is designed to accelerate enrollment in Cidara's CD101 trials and to increase uptake of T2's products..  Full Article

Cidara Q2 net loss per share $0.99​
Wednesday, 9 Aug 2017 04:31pm EDT 

Aug 9 (Reuters) - Cidara Therapeutics Inc :Cidara provides corporate update and reports second quarter 2017 financial results.Cidara Therapeutics Inc - qtrly ‍basic and diluted net loss per share $0.99​.  Full Article

Broadfin Capital reports 5.28 percent passive stake in Cidara Therapeutics as of July 7
Thursday, 13 Jul 2017 12:40pm EDT 

July 13 (Reuters) - Broadfin Capital LLC :Broadfin Capital LLC reports a 5.28 percent passive stake in Cidara Therapeutics Inc as of July 7, 2017 - SEC filing.  Full Article